

Lee Fairlie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/156451/publications.pdf>

Version: 2024-02-01

63
papers

8,819
citations

304368

22
h-index

128067

60
g-index

64
all docs

64
docs citations

64
times ranked

16237
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
4	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	13.9	541
5	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.	13.9	447
6	COVID-19 in Africa: care and protection for frontline healthcare workers. <i>Globalization and Health</i> , 2020, 16, 46.	2.4	272
7	Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. <i>Journal of the International AIDS Society</i> , 2013, 16, 18579.	1.2	159
8	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , 2020, 7, e666-e676.	2.1	145
9	Providing comprehensive health services for young key populations: needs, barriers and gaps. <i>Journal of the International AIDS Society</i> , 2015, 18, 19833.	1.2	138
10	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV,the</i> , 2021, 8, e568-e580.	2.1	124
11	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	3.9	96
12	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 1276-1292.	6.3	82
13	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV,the</i> , 2021, 8, e87-e95.	2.1	70
14	Mortality and losses to follow-up among adolescents living with HIV in the le DEA global cohort collaboration. <i>Journal of the International AIDS Society</i> , 2018, 21, e25215.	1.2	56
15	High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. <i>BMC Infectious Diseases</i> , 2011, 11, 28.	1.3	54
16	Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis. <i>Antiviral Therapy</i> , 2011, 16, 417-421.	0.6	53
17	Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 851-863.	4.6	51
18	Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 1113-1121.	2.9	41

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. <i>Lancet HIV</i> , 2022, 9, e309-e322.	2.1	38
20	Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. <i>Global Health Action</i> , 2013, 6, 19248.	0.7	36
21	Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment. <i>PLoS ONE</i> , 2011, 6, e17273.	1.1	35
22	Validity of Neuropsychological Testing in Young African Children Affected by HIV. <i>Journal of Pediatric Infectious Diseases</i> , 2018, 13, 185-201.	0.1	28
23	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3237-3246.	1.3	26
24	Cost and outcomes of paediatric antiretroviral treatment in South Africa. <i>Aids</i> , 2013, 27, 243-250.	1.0	23
25	African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e105-e114.	2.9	23
26	Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 781-785.	1.0	22
27	Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 175-179.	1.1	20
28	Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy. <i>Clinical Infectious Diseases</i> , 2021, 73, e312-e320.	2.9	18
29	Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. <i>Pediatric Pulmonology</i> , 2016, 51, 157-164.	1.0	17
30	Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006-2017. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 127-133.	1.1	17
31	Ambient temperature during pregnancy and risk of maternal hypertensive disorders: A time-to-event study in Johannesburg, South Africa. <i>Environmental Research</i> , 2022, 212, 113596.	3.7	17
32	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25372.	1.2	15
33	Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. <i>Lancet HIV</i> , 2022, 9, e332-e340.	2.1	15
34	CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. <i>Aids</i> , 2015, 29, 2109-2119.	1.0	13
35	Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 486-494.	0.6	12
36	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. <i>Aids</i> , 2021, 35, S117-S125.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. <i>Aids</i> , 2021, 35, 205-211.	1.0	11
38	Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. <i>HIV Clinical Trials</i> , 2018, 19, 209-224.	2.0	10
39	Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review. <i>PLoS ONE</i> , 2021, 16, e0248423.	1.1	10
40	Building capacity in neurodevelopment assessment of children in sub-Saharan Africa: A quality assurance model to implement standardized neurodevelopment testing. <i>Child Neuropsychology</i> , 2019, 25, 466-481.	0.8	8
41	The Challenge of and Opportunities for Transitioning and Maintaining a Continuum of Care Among Adolescents and Young Adults Living with HIV in Resource Limited Settings. <i>Current Tropical Medicine Reports</i> , 2016, 3, 149-157.	1.6	7
42	Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 201-204.	0.6	7
43	Approaches to accelerating the study of new antiretrovirals in pregnancy. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
44	The interaction between equipoise and logistics in clinical trials: A case study. <i>Clinical Trials</i> , 2017, 14, 314-318.	0.7	6
45	Pooled Prevalence of Adverse Pregnancy and Neonatal Outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results From a Systematic Review and Meta-Analyses to Inform Trials of Novel HIV Prevention Interventions During Pregnancy. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	6
46	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
47	Lamivudine monotherapy as a holding regimen for HIV-positive children. <i>PLoS ONE</i> , 2018, 13, e0205455.	1.1	4
48	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 400-405.	1.1	4
49	COVID-19 in pregnancy in South Africa: Tracking the epidemic and defining the natural history. <i>South African Medical Journal</i> , 2020, 110, 729.	0.2	4
50	Lamivudine monotherapy in children and adolescents: The devil is in the detail. <i>South African Medical Journal</i> , 2017, 107, 1055.	0.2	3
51	The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes—A randomized clinical trial. <i>PLoS ONE</i> , 2020, 15, e0228003.	1.1	3
52	HIV retesting in pregnant women in South Africa: Outcomes of a quality improvement project targeting health systems™ weaknesses. <i>Southern African Journal of HIV Medicine</i> , 2018, 19, 784.	0.3	3
53	Time to implement 9-month infant HIV testing in South Africa. <i>South African Medical Journal</i> , 2015, 105, 765.	0.2	2
54	Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. <i>PLoS ONE</i> , 2021, 16, e0255250.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa. PLoS ONE, 2016, 11, e0145911.	1.1	2
56	Current perspectives on paediatric HIV management from the Mexico International Aids Society Conference, 2019. Southern African Journal of HIV Medicine, 2019, 20, 1027.	0.3	2
57	Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 450-454.	0.9	1
58	Effects of preconception antiretroviral therapy in placenta development and pregnancy outcomes. Aids, 2021, 35, 1139-1141.	1.0	1
59	Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. Clinical Trials, 2021, 18, 174077452110457.	0.7	1
60	Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS ONE, 2017, 12, e0178075.	1.1	1
61	Evaluation of Parent-Child Pairs on Antiretroviral Therapy in Separate Adult and Pediatric Clinics. Journal of the International Association of Providers of AIDS Care, 2014, 13, 555-559.	0.6	0
62	Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE, 2020, 15, e0233693.	1.1	0
63	Combination HIV prevention reduces orphanhood in Uganda. Lancet HIV, the, 2022, 9, e5-e6.	2.1	0